Lyme Disease Clinical Trial
Official title:
A Phase 3, Multicenter, Placebo-Controlled, Randomized, Observer-Blinded Trial to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, and Lot Consistency of a 6-Valent OspA-Based Lyme Disease Vaccine in Healthy Participants ≥5 Years of Age
The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,000 healthy participants 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a 50% chance of receiving VLA15 and about a 50% chance of receiving placebo. A subset of participants will receive VLA15 from 3 different lots or placebo (1:1:1:3 ratio) to assess lot equivalence. Participants will receive a 3-dose primary vaccination series at about 0, 2, and 5 to 9 months and then receive a booster dose about 12 months later. Vaccination of participants will occur at a time of year such that the primary series is completed before the peak Lyme disease season followed by a booster dose just prior to the beginning of the second Lyme disease season. Comparison will be made between the Lyme disease cases of people receiving the study vaccine to those of the people who are not. This will help us determine if the study vaccine is safe and effective. If enrolled, participants will need to visit the research site at least 7 times during the study. There will also be at least 5 telephone contacts. It is expected that each participant will take part in this study for up to about 2 and a half years.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01207739 -
Persistent Lyme Empiric Antibiotic Study Europe
|
Phase 4 | |
| Terminated |
NCT04577053 -
PEMF Therapy to Treat Lingering Symptoms of Lyme Disease After Treatment With Antibiotics
|
N/A | |
| Completed |
NCT04867473 -
Feasibility of Teleyoga for Treatment of Lyme Disease
|
N/A | |
| Recruiting |
NCT04038346 -
Symptomatic Management of Lyme Arthritis
|
Phase 3 | |
| Completed |
NCT01143558 -
Searching for Persistence of Infection in Lyme Disease
|
Early Phase 1 | |
| Withdrawn |
NCT04318925 -
Evaluation and Follow-up of People With Tick-borne Diseases
|
||
| Terminated |
NCT03581279 -
Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel
|
N/A | |
| Enrolling by invitation |
NCT05041595 -
Lyme Disease Diagnostic Assay - Collection of Whole Blood
|
||
| Recruiting |
NCT03981874 -
Peripheral Facial Paralysis Sequelae in Lyme Disease Among Children
|
N/A | |
| Recruiting |
NCT03963635 -
Novel Diagnostics for Early Lyme Disease
|
||
| Terminated |
NCT03084614 -
CD8 Reactivity to Microorganisms in Blood and Breast Milk
|
||
| Recruiting |
NCT04835792 -
Biomarker Study of Previously Treated Lyme Disease Volunteers in Comparison to Healthy Volunteers
|
||
| Recruiting |
NCT04148222 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Lyme Disease
|
||
| Terminated |
NCT03201042 -
Lyme Test Indication Combinations (LyTIC) Study
|
||
| Completed |
NCT01368341 -
Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice
|
Phase 4 | |
| Terminated |
NCT00958139 -
Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes
|
Phase 3 | |
| Recruiting |
NCT00001539 -
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
|
||
| Recruiting |
NCT03501407 -
Understanding Tick-borne Diseases
|
||
| Completed |
NCT04422314 -
ImmuneSense Lyme Study
|
||
| Recruiting |
NCT04719962 -
Direct Diagnosis of Disseminated Lyme Borreliosis.
|
N/A |